Valuation: Denali Therapeutics Inc.

Market Cap 4.08B 3.56B 3.29B 3.04B 5.76B 389B 5.86B 39.29B 15.43B 191B 15.3B 14.97B 658B P/E 2026 *
-10.6x
P/E 2027 * -10.7x
Enterprise Value 3.4B 2.98B 2.74B 2.53B 4.81B 324B 4.89B 32.79B 12.88B 160B 12.77B 12.49B 549B EV / Sales 2026 *
83x
EV / Sales 2027 * 30.1x
Free-Float
90.08%
Yield 2026 *
-
Yield 2027 * -
1 day-5.62%
1 week-0.58%
Current month-0.16%
1 month+18.56%
3 months+33.54%
6 months+43.06%
Current year+55.54%
1 week 25.25
Extreme 25.25
27.3
1 month 21.41
Extreme 21.41
27.3
Current year 15.34
Extreme 15.34
27.3
1 year 12.58
Extreme 12.58
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
67.54
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap.
06-03
Baker Bros. Advisors LP
FreeCompany 51,268 0.0323%
06-03Free

Director

25,634 0.0162%
06-03Free

Director

25,634 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
-5.62%-0.58%+76.86%-12.83% 4.08B
+1.84%-0.66%+59.82%+94.48% 54.88B
+0.58%-5.51%+57.61%+130.90% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
-1.69%-1.27%+39.51%-8.30% 19.87B
+0.45%+2.68%+36.77%-27.46% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.42%-3.72%+47.02%+635.77% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average -1.85%-0.31%+53.75%+182.20% 24.56B
Weighted average by Cap. -0.71%-1.44%+50.92%+170.06%

Financials

2026 *2027 *
Net sales 41M 35.86M 33.08M 30.55M 57.97M 3.91B 58.95M 395M 155M 1.93B 154M 151M 6.62B 113M 98.99M 91.31M 84.33M 160M 10.79B 163M 1.09B 428M 5.32B 425M 416M 18.28B
Net income -482M -421M -389M -359M -681M -45.93B -692M -4.64B -1.82B -22.62B -1.81B -1.77B -77.78B -463M -405M -374M -345M -655M -44.2B -666M -4.47B -1.75B -21.77B -1.74B -1.7B -74.86B
Net Debt -674M -590M -544M -503M -954M -64.32B -970M -6.5B -2.55B -31.69B -2.53B -2.48B -109B -665M -581M -536M -495M -940M -63.4B -956M -6.41B -2.52B -31.23B -2.5B -2.44B -107B
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
507
Date Price Change Volume
10/07/26 $25.68 -5.62% 1,397,862
09/07/26 $27.21 +1.95% 1,567,389
08/07/26 $26.69 +1.44% 1,300,642
07/07/26 $26.31 +2.21% 1,437,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
25.68USD
Average target price
33.93USD
Spread / Average Target
+32.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DNLI Stock